Publications by authors named "D Cronin-Fenton"
Background: Breast cancer patients with low socioeconomic position (SEP) have a higher risk of recurrence and mortality. We examined the extent to which prior psychiatric medication impacted this association.
Methods: We conducted a cohort study of premenopausal women diagnosed with breast cancer in Denmark from 2002 to 2011 (n = 5847), linking data from Denmark's nationwide population-based health registries on breast cancer diagnosis, treatment, psychiatric medication prescriptions and SEP indicators (marital status, cohabitation, income, education and employment).
Purpose: Data on type 2 diabetes (T2D) risk after breast cancer (BC) could guide preventive strategies. Yet, studies had limitations regarding sample size, follow-up, and contemporary treatments. We evaluated the risk of T2D after BC overall, by cancer treatment, and compared with a matched cohort of cancer-free women.
View Article and Find Full Text PDFBackground: Influenza vaccination is free of charge for Danish citizens with acquired immunodeficiency but recommendations do not specifically target patients with cancer. This study investigated whether influenza vaccination reduces the main outcome of overall mortality and the secondary outcomes of influenza requiring treatment, pneumonia, myocardial infarction, stroke, heart failure, and venous thromboembolism in patients with cancer.
Methods: This was a register-based nationwide cohort study.
Article Synopsis
- The study aimed to explore whether certain genetic variants (SNPs) related to taxane chemotherapy affect breast cancer patients' need for social benefits after treatment.
- Researchers analyzed data from premenopausal women diagnosed with breast cancer, focusing on their receipt of health and labor market-related benefits over a five-year period.
- The findings indicated that there was no significant link between the selected SNPs and the likelihood of receiving social benefits post-chemotherapy.
Purpose: Breast cancer has an average 10-year relative survival reaching 84%. This favorable survival is due, in part, to the introduction of biomarker-guided therapies. We estimated the population-level effect of the introduction of two adjuvant therapies-tamoxifen and trastuzumab-on recurrence using the trend-in-trend pharmacoepidemiologic study design.
View Article and Find Full Text PDF